Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Daniel_Burgess
|
| gptkbp:clinicalTrialPhase |
gptkb:PC945_Phase_3
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:developedBy |
antifungal therapies
|
| gptkbp:focusesOn |
respiratory diseases
|
| gptkbp:foundedIn |
2007
|
| gptkbp:founder |
gptkb:Garth_Rapeport
gptkb:Pete_Strong |
| gptkbp:fundedBy |
Venture capital investors
|
| gptkbp:headquartersLocation |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pulmocide
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:PC786Indication |
respiratory syncytial virus (RSV) infection
|
| gptkbp:PC945Indication |
invasive pulmonary aspergillosis
|
| gptkbp:product |
gptkb:PC786
gptkb:PC945 |
| gptkbp:website |
https://www.pulmocide.com/
|
| gptkbp:bfsParent |
gptkb:F-Prime_Capital
gptkb:F-Prime_Capital_Partners |
| gptkbp:bfsLayer |
6
|